Back to search

University of Crete (UOC)

Study of metabolic pathways for the detection of biomarkers in hashimoto's thyroiditis and psoriasis

Abstract

dc:description

SUMMARY BACKGROUND: Hashimoto’s thyroiditis (HT) and psoriasis (PSO) are common autoinflammatory disorders with a significant impact on patients’ quality of life. Aetiopathogenesis includes complex molecular pathways and interconnections between the immune system and tissue cells, for which metabolism plays a key role. Metabolomics, a field of omics sciences studying the molecular intermediates of biochemical reactions, has been increasingly used for biomarker discovery in clinical research. However, there is limited data available on its application in HT and PSO. AIM: The present PhD study had two primary aims: first, to identify common and disease-specific metabolic biomarkers in HT and PSO, and second, to study the changes in metabolic biomarkers and patients' quality of life (QoL) following a dietary intervention. METHODS: A randomized clinical trial was undertaken, enrolling 194 participants, including 66 patients with HT, 64 patients PSO, and 64 healthy individuals (CO) aged 18–60. Participants in the HT group had normal thyroid function maintained through hormone replacement therapy, while PSO patients had controlled symptomatology through topical or systemic treatment. All participants had normal levels of body mass index (BMI), and baseline assessments confirmed no significant differences in gender, age, smoking habits, alcohol consumption, or dietary habits, as evaluated using the Mediterranean Diet Score (MEDAS). Participants were randomized into two groups: the intervention group received a combination of nutraceuticals (multivitamins, vitamin C, vitamin D, calcium, magnesium, glutamine, probiotics, and polyunsaturated fatty acids) along with a Mediterranean diet for six months. The control group was requested to continue their usual diet. The outcome measures included changes in metabolic biomarkers and disease-specific QoL measured using the Thyroid Patient Reported Outcome (ThyPRO) for HT and the Dermatology Life Quality Index (DLQI) for PSO. Results on metabolic biomarkers: Baseline metabolic profiling revealed significant disruptions in HT and PSO, with distinct and shared biomarkers reflecting the underlying metabolic dysfunctions that likely contribute to inflammation and disease progression. Both conditions were characterized by altered fatty acid metabolism, which might be associated with common immunopathogenic mechanisms. In addition, mitochondrial dysfunction, microbiome metabolism and micronutrient bioavailability-associated metabolites were commonly affected in both conditions. For patients with HT, changes in the tricarboxylic acid cycle (TCA), carbohydrate, neurotransmitter, microbiome and lipid metabolism were reported compared to CO. Specifically, levels of methyl succinic acid, 3-Hydroxybutyric acid, methylmalonic, 4-hydroxyphenyl pyruvic acid, fumaric/succinic ratio, C20:3n6, C161n7, C16:0, C141,total saturated FA (SFA) and C161n7/C16:0 ratio were statistically significantly2different than the CO group (p<0.0001). Additional metabolic changes at a nominal significance level included citric acid, isocitric acid, 2-ketoglutaric acid, pyruvic acid, vanillylmandelic acid, glyceric acid and methylcitric acid (p<0.05). When the results were adjusted for gender, age, ΒMI, smoking, MEDAS, alcohol and exercise, methylmalonic acid, C16:0, C141, SFA and C161n7/C16:0 ratio remained significantly associated with the presence of HT. Therefore, these metabolites could serve as potential biomarkers. Overall, the present study showed an association of HT with mitochondrial dysfunction and energy metabolism, micronutrient-decreased bioavailability, microbiome imbalances, and carbohydrate and fatty acids dysfunctional metabolism. For patients with PSO, metabolic profiling revealed statistically significant differences in energy metabolism pathways (TCA and glycolytic-mediated), microbiome and lipid metabolism. Specifically, levels of glycolic acid, methylsuccinic acid, orotic acid and the ratios isocitric/citric and aconitic/citric, C18:3n3, C20:3n3, C18:2n6, C18:3n6,C20:5n3, C22:1n9, total PUFA and SFA/total ratio were statistically significantly altered compared to the CO (p<0.0001). Additional metabolic changes at a nominal significance level included 2-ketoglutaric acid, malic acid, 3-hydroxy-3-methylglutaricacid, pyruvic acid, pyroglutamic acid, 2-hydroxyisobyturic acid, 2-hydroxyphenylpyruvic acid and methylcitric acid (p<0.05). Among the tested metabolites, aconitic/isocitric acid, C18:3n3, C20:3n3, C20:5n3, C18:3n6 and C18:2n6were significantly associated with PSO adjusting for gender, age, ΒMI, smoking, treatment, MDS, alcohol and exercise and could serve as potent biomarkers. BMI was associated with aconitic/isocitric acid and C18:3n3 in these models. INTERVENTION RESULTS: The randomized clinical trial results showed that patients in the intervention group demonstrated significant improvements in metabolic biomarkers and quality of life. Metabolomic analysis of the HT group receiving the intervention(HT:26) identified statistically significant changes in methyl succinic acid, suberic acid,5-Hydroxyindoloacetic/ Vanillylmandelic ratio, adipic acid, 3-hydroxy isovaleric acid ,C20:3n3, C20:5n3, C12:0 and C14:1/C14:0 ratio C20:4n6/C20:5n3 ratio andOmega6/Omega3 ratio. Any markers that showed changes in the HT group that did not receive the intervention were excluded, as they represent random variations unrelated to the intervention. Omega6/Omega3 ratio and C20:4n6/C20:5n3 ratio changes remained significantly associated with the intervention after adjustment for potential confounders. Patients who received the intervention reported markedly reduced Tiredness and Depressivity and reduced Goiter and Hyperthyroid symptoms in the ThyPRO scores. These differences remained significant after adjusting for confounding factors of age, ΒMI, gender, alcohol, exercise, and smoking. Furthermore, improvement in Tiredness and Depressivity was observed even when minimal important change cutoff was applied, representing a clinically meaningful improvement.3Associations between QoL improvement and metabolic biomarkers were detected for Tiredness and the following metabolites: From the mitochondrial function panel (TCA cycle), citric acid, aconitic acid, isocitric acid, 2-ketoglutaric acid, malic acid and 3-hydroxy-3-methylglutaric acid, and the adrenaline metabolite, vanillylmandelic acid. For Goiter and Hyperthyroid symptoms, associations were detected with lactic acid and pyruvic acid, participating in carbohydrate metabolism, methylmalonic acid (vitaminB12 marker), glycolic acid and ethylmalonic acid (protein and fatty acids metabolism)and methylcitric acid (microbiome marker). The observed correlations were statistically significant though relatively weak (below or marginally above 0.5), potentially due to the small sample. From the TFA panel, associations were stronger, allowing the development of regression predictive models. The omega6/omega 3 ratio was significantly associated with the Goiter and Hyperthyroid symptoms score, which was adjusted for confounders, including demographics, lifestyle habits, and the intervention. BMI was significantly associated with tiredness, hyperthyroid symptoms and depressivity and associations were identified for gender and hyperthyroid and depressivity. Overall, these findings suggest that the administration of nutraceutical supplementation can be associated with improvement in the QoL of patients with HT, and metabolites could serve as potent response-to-treatment biomarkers. Metabolomic analysis of the PSO group that received the intervention (PSO:21)identified statistically significant changes in malic acid, lactic acid, pyroglutamic acid, methylmalonic acid, 5-HIAA, adipic acid and 4-hydroxyphenylpyruvic acid. On the other hand, a pairwise analysis of the fatty acids in the intervention and the non-intervention groups of PSO yielded results with similar metabolic differences. Compared to the untreated group, patients who received the intervention (n:14) reported reduced DLQI scores, indicating an improved quality of life associated with the dermatological condition. In addition, changes in the frequency of DLQI scores showed that 68.8% of the participants reported a DLQI score of 2 or less compared to 35.7% before the treatment. Overall, these findings suggest that the administration of nutraceutical supplementation might be associated with changes in the quality of life of patients with psoriasis, and metabolites might serve as adjunct biomarkers. Conclusion: In conclusion, the present study demonstrates the crucial role of metabolic dysregulation in Hashimoto’s thyroiditis and psoriasis, identifying potential metabolic biomarkers and providing evidence that addressing the underlying metabolic dysfunctions in addition to conventional therapy, can improve the disease-associated quality of life of patients.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sarandi, Evangelia
  • Σαράντη, Ευαγγελία

Subjects

dc:subject × 12

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58096

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sarandi, Evangelia; Σαράντη, Ευαγγελία. Study of metabolic pathways for the detection of biomarkers in hashimoto's thyroiditis and psoriasis. University of Crete (UOC), 2024. http://hdl.handle.net/10442/hedi/58096